Literature DB >> 30057123

Preoperative strategies to improve resectability for hepatocellular carcinoma: a systematic review and meta-analysis.

Francisco Tustumi1, Lucas Ernani2, Fabricio F Coelho2, Wanderley M Bernardo2, Sérgio S Junior2, Jaime A P Kruger2, Gilton M Fonseca2, Vagner B Jeismann2, Ivan Cecconello2, Paulo Herman2.   

Abstract

BACKGROUND: Preoperative strategies to increase the future liver remnant are useful methods to improve resectability rates for patients with hepatocellular carcinoma (HCC). The aim of this study was to perform a systematic review and meta-analysis of the main strategies used for this purpose.
METHODS: A systematic review was performed in PubMed, EMBASE, Cochrane and Scielo/LILACS. The procedures included for analysis were portal vein embolization or ligation (PVE/PVL), sequential transarterial embolization and PVE (TACE + PVE), radioembolization (RE) and associated liver partition and portal vein ligation for staged hepatectomy (ALPPS). Perioperative morbidity and mortality, post-hepatectomy liver failure (PHLF), and survival rates were evaluated.
RESULTS: A total of 46 studies were included in the systematic review (1284 patients). Resection rate was higher in TACE + PVE (90%; N = 315) when compared to PVE/PVL (75%; N = 254; P = <0.001) and similar to ALPPS (84%; N = 43; P = 0.374) and RE (100%; N = 28; P = 0.14). ALPPS was associated with higher PHLF and perioperative mortality rates when compared to PVE/PVL and TACE + PVE. ALPPS and RE showed higher risk of major complications than PVE/PVL and TACE + PVE.
CONCLUSION: Preoperative strategies to increase liver volume are effective in achieving resectability of HCC. TACE + PVE is as safe as PVL/PVE providing higher OS. ALPPS is associated with a higher risk of PHLF, major complications, and mortality. RE despite the small experience seems to present similar resection rate and OS as TACE + PVE with higher rate of major complications.
Copyright © 2018 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30057123     DOI: 10.1016/j.hpb.2018.06.1798

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  16 in total

1.  Ipsilateral access portal venous embolization (PVE) for preoperative hypertrophy exhibits low complication rates in Clavien-Dindo and CIRSE scales.

Authors:  Roland Brüning; Martin Schneider; Michel Tiede; Peter Wohlmuth; Gregor Stavrou; Thomas von Hahn; Andrea Ehrenfeld; Tim Reese; Georgios Makridis; Axel Stang; Karl J Oldhafer
Journal:  CVIR Endovasc       Date:  2021-05-17

Review 2.  Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition).

Authors:  Hui-Chuan Sun; Jian Zhou; Zheng Wang; Xiufeng Liu; Qing Xie; Weidong Jia; Ming Zhao; Xinyu Bi; Gong Li; Xueli Bai; Yuan Ji; Li Xu; Xiao-Dong Zhu; Dousheng Bai; Yajin Chen; Yongjun Chen; Chaoliu Dai; Rongping Guo; Wenzhi Guo; Chunyi Hao; Tao Huang; Zhiyong Huang; Deyu Li; Gang Li; Tao Li; Xiangcheng Li; Guangming Li; Xiao Liang; Jingfeng Liu; Fubao Liu; Shichun Lu; Zheng Lu; Weifu Lv; Yilei Mao; Guoliang Shao; Yinghong Shi; Tianqiang Song; Guang Tan; Yunqiang Tang; Kaishan Tao; Chidan Wan; Guangyi Wang; Lu Wang; Shunxiang Wang; Tianfu Wen; Baocai Xing; Bangde Xiang; Sheng Yan; Dinghua Yang; Guowen Yin; Tao Yin; Zhenyu Yin; Zhengping Yu; Bixiang Zhang; Jialin Zhang; Shuijun Zhang; Ti Zhang; Yamin Zhang; Yubao Zhang; Aibin Zhang; Haitao Zhao; Ledu Zhou; Wu Zhang; Zhenyu Zhu; Shukui Qin; Feng Shen; Xiujun Cai; Gaojun Teng; Jianqiang Cai; Minshan Chen; Qiang Li; Lianxin Liu; Weilin Wang; Tingbo Liang; Jiahong Dong; Xiaoping Chen; Xuehao Wang; Shusen Zheng; Jia Fan
Journal:  Hepatobiliary Surg Nutr       Date:  2022-04       Impact factor: 7.293

3.  Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations.

Authors:  Xiao-Dong Zhu; Cheng Huang; Ying-Hao Shen; Yuan Ji; Ning-Ling Ge; Xu-Dong Qu; Lingli Chen; Wen-Kai Shi; Mei-Ling Li; Jin-Jin Zhu; Chang-Jun Tan; Zhao-You Tang; Jian Zhou; Jia Fan; Hui-Chuan Sun
Journal:  Liver Cancer       Date:  2021-03-30       Impact factor: 11.740

4.  Toxicity Profiles of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.

Authors:  Christopher D Griffiths; Betty Zhang; Kasia Tywonek; Brandon M Meyers; Pablo E Serrano
Journal:  JAMA Netw Open       Date:  2022-07-01

5.  One- versus two-stage partial hepatectomy for large resectable solitary hepatocellular carcinomas determined preoperatively to have a narrow resection margin: a propensity score matching analysis.

Authors:  Yao Li; Peng-Peng Li; Da-Peng Sun; Jun-Sheng Ni; Wan Yee Lau; Gang Huang; Wei-Ping Zhou; Hui Liu; Ze-Ya Pan; Yuan Yang; Ling-Hao Zhao
Journal:  Hepatobiliary Surg Nutr       Date:  2022-10       Impact factor: 8.265

6.  Transarterial Chemoembolization Combined With Hepatectomy for the Treatment of Intermediate-Stage Hepatocellular Carcinoma.

Authors:  Qunfang Zhou; Fei Tuo; Ruixia Li; Xiaohui Wang; Juncheng Wang; Zhimei Huang; Minshan Chen; Jinhua Huang
Journal:  Front Oncol       Date:  2020-11-04       Impact factor: 6.244

7.  Perioperative impact of liver venous deprivation compared with portal venous embolization in patients undergoing right hepatectomy: preliminary results from the pioneer center.

Authors:  Fabrizio Panaro; Fabio Giannone; Benjamin Riviere; Olivia Sgarbura; Caterina Cusumano; Emmanuel Deshayes; Francis Navarro; Boris Guiu; Francois Quenet
Journal:  Hepatobiliary Surg Nutr       Date:  2019-08       Impact factor: 7.293

Review 8.  Uncommon indications for associating liver partition and portal vein ligation for staged hepatectomy: a systematic review.

Authors:  Quirino Lai; Gianluca Mennini; Zoe Larghi Laureiro; Massimo Rossi
Journal:  Hepatobiliary Surg Nutr       Date:  2021-04       Impact factor: 8.265

9.  Liver resection versus transarterial chemoembolization for huge hepatocellular carcinoma: a propensity score matched analysis.

Authors:  A Bogdanovic; P Bulajic; D Masulovic; N Bidzic; M Zivanovic; D Galun
Journal:  Sci Rep       Date:  2021-02-24       Impact factor: 4.379

Review 10.  Embolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update.

Authors:  Sirish A Kishore; Raazi Bajwa; David C Madoff
Journal:  Cancers (Basel)       Date:  2020-03-26       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.